AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
Favorable Final Height Outcome in Girls with Ullrich-Turner Syndrome Treated with Low-Dose Growth Hormone Together with Oxandrolone Despite Starting Treatment After 10 Years of Age
The objective of this study was to find out whether moderate doses of growth hormone ( GH ) in combination with ox and rolone ( Ox ) and late initiation of puberty could improve adult height even in relatively old patients with Ullrich-Turner syndrome ( UTS ) . Ninety-one patients with UTS were r and omly assigned to receive either GH alone ( Saizen , Ares-Serono , Geneva ) 18 IU/m2/week ( 0.2 mg/kg/week ) by daily s.c . injections ( group GH ) or a combination of GH and Ox 0.1 mg/kg/day p.o . ( group GH + Ox ) . Prior to treatment mean age was 10.2 years ( GH ) and 10.5 years ( GH + Ox ) , mean projected adult height ( PAH ) was 146.4 cm ( GH ) and 146.7 cm ( GH + Ox ) . During year 2 the GH dose was increased in the GH group to 24 and later to 28 IU/m2/week ( 0.27 mg and later 0.31 mg/kg/week ) . In group GH + Ox , the Ox dose was reduced to 0.05 mg/kg/day after the first 12 months of therapy , and during the last treatment years the GH dose was raised to 24 - 28 IU/m2/week ( 0.27 - 0.31 mg/kg/week ) due to declining growth promotion . Some of the patients of group GH were later given Ox in addition to GH because of waning growth velocity , whereas some of the patients of group GH + Ox were taken off Ox due to virilizing side-effects of the high Ox dose , thus making up a third group of patients : group GH + transient Ox . Puberty was induced at a mean age of 14.9 years . In group GH + Ox , cumulative growth during 5 years of therapy was twice the growth anticipated from st and ards of untreated patients with UTS . Forty-seven patients are now near or at final height : in group GH ( n = 7 ) , mean final height was 151.7 cm ( PAH 148.1 cm , gain 3.6 cm ) ; in group GH + Ox ( n = 15 ) , 155.1 cm ( PAH 147.2 cm , gain 7.9 cm ) ; and in group GH + transient Ox ( n = 25 ) , 152.8 cm ( PAH 146.4 cm , gain 6.4 cm ) . These results should be regarded as an underestimate of true final height since some the patients are still growing . Moderate doses of GH plus Ox and late induction of puberty definitely improved final height even in patients with UTS treated relatively late
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .